应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02493 迈威生物-B
已收盘 09-02 16:08:05
20.780
+0.260
+1.27%
最高
21.980
最低
20.320
成交量
42.14万
今开
21.000
昨收
20.520
日振幅
8.09%
总市值
92.89亿
流通市值
9.79亿
总股本
4.47亿
成交额
889.41万
换手率
0.89%
流通股本
4,713万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
迈威生物-B盘中涨超7% 上半年营收毛利双双大幅增长
新浪港股 · 11:33
迈威生物-B盘中涨超7% 上半年营收毛利双双大幅增长
港股异动 | 迈威生物-B(02493.HK)盘中涨超5% 上半年营收毛利双双大幅增长 9MW2821已进入关键临床阶段
智通财经 · 11:07
港股异动 | 迈威生物-B(02493.HK)盘中涨超5% 上半年营收毛利双双大幅增长 9MW2821已进入关键临床阶段
迈威生物（688062）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月1日股价下跌1.62%
证券之星 · 09-01 22:51
迈威生物（688062）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月1日股价下跌1.62%
迈威生物-B（02493）拟于9月16日出席科创板2026年半年度创新药行业集体业绩说明会
公告速递 · 09-01 17:57
迈威生物-B（02493）拟于9月16日出席科创板2026年半年度创新药行业集体业绩说明会
迈威生物（688062）2026年中报简析：营收上升亏损收窄
证券之星 · 09-01 06:09
迈威生物（688062）2026年中报简析：营收上升亏损收窄
迈威生物：关于变更经营范围、修订《公司章程》并办理工商变更登记的公告
证券日报 · 08-30 20:23
迈威生物：关于变更经营范围、修订《公司章程》并办理工商变更登记的公告
迈威生物：第三届董事会第二次会议决议公告
证券日报 · 08-30 20:21
迈威生物：第三届董事会第二次会议决议公告
迈威生物-B(02493)9月17日召开第四次临时股东会 将审议许可交易及经营范围变更
公告速递 · 08-30 18:31
迈威生物-B(02493)9月17日召开第四次临时股东会 将审议许可交易及经营范围变更
迈威生物：与思努赛签订SST001项目许可协议暨关联交易
格隆汇 · 08-30 18:30
迈威生物：与思努赛签订SST001项目许可协议暨关联交易
迈威生物-B(02493)拟调整经营范围并修订公司章程
公告速递 · 08-30 18:25
迈威生物-B(02493)拟调整经营范围并修订公司章程
迈威生物-B(02493)上半年营收、毛利大幅增长 核心管线取得多项关键临床里程碑
智通财经 · 08-30 18:25
迈威生物-B(02493)上半年营收、毛利大幅增长 核心管线取得多项关键临床里程碑
迈威生物-B(02493.HK)上半年营收、毛利大幅增长 核心管线取得多项关键临床里程碑
智通财经 · 08-30 18:25
迈威生物-B(02493.HK)上半年营收、毛利大幅增长 核心管线取得多项关键临床里程碑
迈威生物-B2026年中期营收3.12亿元
公告速递 · 08-30 18:17
迈威生物-B2026年中期营收3.12亿元
迈威生物：2026年半年度净亏损5.22亿元
证券之星 · 08-30 18:11
迈威生物：2026年半年度净亏损5.22亿元
图解迈威生物中报：第二季度单季净利润同比下降7.77%
证券之星 · 08-30 17:45
图解迈威生物中报：第二季度单季净利润同比下降7.77%
迈威生物(688062)6月30日股东户数1.85万户，较上期减少2.76%
证券之星 · 08-30 17:07
迈威生物(688062)6月30日股东户数1.85万户，较上期减少2.76%
海欣股份：公司通过锚定投资方式参与迈威生物-B的投资
证券之星 · 08-25
海欣股份：公司通过锚定投资方式参与迈威生物-B的投资
8月24日迈威生物跌6.22%，中航优选领航混合发起A基金重仓该股
证券之星 · 08-24
8月24日迈威生物跌6.22%，中航优选领航混合发起A基金重仓该股
迈威生物-B（02493）将于2026年8月30日审议2026年中期业绩
公告速递 · 08-19
迈威生物-B（02493）将于2026年8月30日审议2026年中期业绩
8月19日迈威生物跌5.45%，中航优选领航混合发起A基金重仓该股
证券之星 · 08-19
8月19日迈威生物跌5.45%，中航优选领航混合发起A基金重仓该股
加载更多
公司概况
公司名称：
迈威生物-B
所属市场：
SEHK
上市日期：
--
主营业务：
公司是一家全产业链布局的创新型生物制药公司,始终秉承“让创新从梦想变成现实”的愿景,践行“探索生命,惠及健康”的使命,通过源头创新,为患者提供疗效更好、可及性更强的生物创新药,满足全球未被满足的临床需求。公司主营业务为研发、生产以及销售创新型药物和生物类似药。公司主要产品为抗体、ADC药物和重组蛋白、小分子化学药等药物。公司荣誉:上海产业人才队伍建设工作“优秀案例奖”、澳洲会计师公会“认可雇主”、星耀榜“2021中国生物创新药最具成长性年度大奖”、中国医药人才品牌榜总榜及最具竞争力品牌等。
发行价格：
--
{"stockData":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"迈威生物-B","latestPrice":20.78,"timestamp":1788336485753,"preClose":20.52,"halted":0,"volume":421400,"delay":0,"changeRate":0.012670565302144325,"floatShares":47130200,"shares":447000000,"eps":-2.43,"marketStatus":"已收盘","change":0.26,"latestTime":"09-02 16:08:05","open":21,"high":21.98,"low":20.32,"amount":8894144,"amplitude":0.080897,"askPrice":20.82,"askSize":400,"bidPrice":20.6,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-2.422,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788399000000},"marketStatusCode":5,"adr":0,"listingDate":1777305600000,"exchange":"SEHK","adjPreClose":20.52,"openAndCloseTimeList":[[1788312600000,1788321600000],[1788325200000,1788336000000]],"volumeRatio":2.057617,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物-U","latestPrice":27.53,"timestamp":1788332400000,"preClose":27.87,"halted":0,"volume":6029000,"delay":0,"premium":"-35.29"}},"requestUrl":"/m/hq/s/02493","defaultTab":"news","newsList":[{"id":"2664893150","title":"迈威生物-B盘中涨超7% 上半年营收毛利双双大幅增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2664893150","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664893150?lang=zh_cn&edition=full","pubTime":"2026-09-02 11:33","pubTimestamp":1788319980,"startTime":"0","endTime":"0","summary":"模拟交易客户端迈威生物-B盘中涨超7%，截至发稿，涨幅回落，股价上涨1.56%，现报20.84港元，成交额699.858万港元。迈威生物-B近日公布2026年中期业绩，公司收入约3.12亿元，同比增长209.06%；毛利约2.36亿元，同比增长198.67%；研发成本约4.31亿元，同比增长约10%。收入增加主要由于 Kalexo及Disc的对外授权收入增加，以及君迈康的药品的销售收入增加导致收入增加所致。公告称，核心产品9MW2821已进入关键临床阶段，并获得多项突破性疗法认定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-02/doc-iniqkzky4624441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664893391","title":"港股异动 | 迈威生物-B(02493.HK)盘中涨超5% 上半年营收毛利双双大幅增长 9MW2821已进入关键临床阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2664893391","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664893391?lang=zh_cn&edition=full","pubTime":"2026-09-02 11:07","pubTimestamp":1788318425,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664585745","title":"迈威生物（688062）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月1日股价下跌1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664585745","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664585745?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:51","pubTimestamp":1788274270,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘，迈威生物报收于27.87元，较前一交易日下跌1.62%，最新总市值为124.5亿元。该股当日开盘28.29元，最高28.5元，最低27.61元，成交额达1.54亿元，换手率为2.4%。近日，迈威（上海）生物科技股份有限公司披露公告，公司将于2026年9月16日15:00-17:00参加由上海证券交易所主办的科创板2026年半年度创新药行业集体业绩说明会，通过上证路演中心网络互动方式，就公司2026年半年度经营成果、财务状况等与投资者进行交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100043345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK1161","BK1574","06978","688062","159992","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172525921","title":"迈威生物-B（02493）拟于9月16日出席科创板2026年半年度创新药行业集体业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=1172525921","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172525921?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:57","pubTimestamp":1788256655,"startTime":"0","endTime":"0","summary":"迈威生物-B9月2日公告称，公司将参加由上海证券交易所主办的“科创板2026年半年度创新药行业集体业绩说明会”。会后，投资者可于上证路演中心网站查看会议情况及主要内容。此前，公司已于2026年8月31日披露2026年半年度报告。本次说明会旨在帮助投资者更全面了解公司2026年半年度经营成果与财务状况。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664885260","title":"迈威生物（688062）2026年中报简析：营收上升亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2664885260","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664885260?lang=zh_cn&edition=full","pubTime":"2026-09-01 06:09","pubTimestamp":1788214142,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期迈威生物发布2026年中报。根据财报显示，迈威生物营收上升亏损收窄。财报体检工具显示：建议关注公司现金流状况建议关注公司债务状况建议关注财务费用状况建议关注公司应收账款状况持有迈威生物最多的基金为中航优选领航混合发起A，目前规模为0.62亿元，最新净值1.6138，较上一交易日下跌1.06%，近一年下跌20.1%。本文数据来源于迈威生物2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100004792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663304463","title":"迈威生物：关于变更经营范围、修订《公司章程》并办理工商变更登记的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2663304463","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663304463?lang=zh_cn&edition=full","pubTime":"2026-08-30 20:23","pubTimestamp":1788092580,"startTime":"0","endTime":"0","summary":"8月30日，迈威生物发布公告称，公司于2026年8月30日召开第三届董事会第二次会议，审议通过《关于变更经营范围、修订并办理工商变更登记的议案》。公司计划在原经营范围基础上，增加人体基因诊断与治疗技术开发、细胞技术研发和应用等经营范围，并修订《公司章程》相关条款；上述事项尚需提交股东会审议，变更内容以工商登记机关最终核准为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608303859482867.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608303859482867.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663204455","title":"迈威生物：第三届董事会第二次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2663204455","media":"证券日报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663204455?lang=zh_cn&edition=full","pubTime":"2026-08-30 20:21","pubTimestamp":1788092460,"startTime":"0","endTime":"0","summary":"8月30日，迈威生物发布公告称，公司于2026年8月30日召开第三届董事会第二次会议，审议通过《关于公司〈2026年半年度报告〉〈2026年半年度报告摘要〉〈截至二零二六年六月三十日止六个月期间中期业绩公告〉的议案》《关于公司〈2026年半年度募集资金存放与实际使用情况的专项报告〉的议案》《关于与思努赛签订许可协议暨关联交易的议案》等多项议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608303859480878.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608303859480878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144709081","title":"迈威生物-B(02493)9月17日召开第四次临时股东会 将审议许可交易及经营范围变更","url":"https://stock-news.laohu8.com/highlight/detail?id=1144709081","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144709081?lang=zh_cn&edition=full","pubTime":"2026-08-30 18:31","pubTimestamp":1788085865,"startTime":"0","endTime":"0","summary":"以上议案将按香港上市规则以投票方式表决。迈威生物-B提示股东按时完成股份过户及委任代表手续，以保障表决权。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663990041","title":"迈威生物：与思努赛签订SST001项目许可协议暨关联交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2663990041","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663990041?lang=zh_cn&edition=full","pubTime":"2026-08-30 18:30","pubTimestamp":1788085834,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116393080","title":"迈威生物-B(02493)拟调整经营范围并修订公司章程","url":"https://stock-news.laohu8.com/highlight/detail?id=1116393080","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116393080?lang=zh_cn&edition=full","pubTime":"2026-08-30 18:25","pubTimestamp":1788085530,"startTime":"0","endTime":"0","summary":"迈威生物-B8月30日公告称，董事会已审议并通过有关变更经营范围、修订公司章程及办理工商变更登记的议案，拟提交股东于临时股东大会以特别决议案审议。若获批准，公司章程将同步修订，修订案自临时股东大会通过之日起生效；在此之前，现行章程继续适用。本公告由迈威生物-B董事长及执行董事刘大涛博士代表董事会发布。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663943041","title":"迈威生物-B(02493)上半年营收、毛利大幅增长 核心管线取得多项关键临床里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2663943041","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663943041?lang=zh_cn&edition=full","pubTime":"2026-08-30 18:25","pubTimestamp":1788085515,"startTime":"0","endTime":"0","summary":"展望未来，公司将将加速核心产品试验阶段进程，目前公司核心自研的Nectin-4靶向 ADC产品9MW2821临床进度位居国内首位、全球第二，亦是全球首个推进至宫颈癌III期注册临床的同靶点药物，目前尿路上皮癌单药、联合免疫治疗及宫颈癌三项核心适应症正处于III期临床的关键攻坚阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663504194","title":"迈威生物-B(02493.HK)上半年营收、毛利大幅增长 核心管线取得多项关键临床里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2663504194","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663504194?lang=zh_cn&edition=full","pubTime":"2026-08-30 18:25","pubTimestamp":1788085515,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119234178","title":"迈威生物-B2026年中期营收3.12亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119234178","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119234178?lang=zh_cn&edition=full","pubTime":"2026-08-30 18:17","pubTimestamp":1788085048,"startTime":"0","endTime":"0","summary":"迈威生物-B公告显示，截至2026年6月30日止六个月，公司实现营收3.12亿元，较上年同期的1.01亿元增长209.1%。同期公司毛利从0.79亿元提升至2.36亿元，同比增长198.6%。经营活动所用现金净额达5.09亿元，而上年同期为0.34亿元。管理开支从1.19亿元下降至1.08亿元，降幅为9%。公司上半年产品销售收入为2.13亿元，上年同期为1.01亿元，带动收入增长的主要因素包括产品销量提升。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"迈威生物-B2026年中期营收3.12亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663527041","title":"迈威生物：2026年半年度净亏损5.22亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2663527041","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663527041?lang=zh_cn&edition=full","pubTime":"2026-08-30 18:11","pubTimestamp":1788084667,"startTime":"0","endTime":"0","summary":"迈威生物(688062.SH)发布2026年半年度报告，实现营业收入3.13亿元，同比增长209.04%；归属于上市公司股东的净利润为亏损5.22亿元。注：公司Q2净利润亏损2.8亿，Q1净利润-2.42亿，据此计算，Q2净利润环比持续亏损。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000013265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663041842","title":"图解迈威生物中报：第二季度单季净利润同比下降7.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663041842","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663041842?lang=zh_cn&edition=full","pubTime":"2026-08-30 17:45","pubTimestamp":1788083132,"startTime":"0","endTime":"0","summary":"证券之星消息，迈威生物2026年中报显示，上半年度公司主营收入3.13亿元，同比上升209.04%；归母净利润-5.22亿元，同比上升5.37%；扣非净利润-5.18亿元，同比上升9.64%；其中2026年第二季度，公司单季度主营收入1.85亿元，同比上升228.23%；单季度归母净利润-2.8亿元，同比下降7.77%；单季度扣非净利润-2.76亿元，同比上升1.31%；负债率80.09%，投资收益-504.49万元，财务费用6898.99万元，毛利率75.46%。财报数据概要请见下图:本文数据来源于迈威生物2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000012946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663904946","title":"迈威生物(688062)6月30日股东户数1.85万户，较上期减少2.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663904946","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663904946?lang=zh_cn&edition=full","pubTime":"2026-08-30 17:07","pubTimestamp":1788080860,"startTime":"0","endTime":"0","summary":"证券之星消息，近日迈威生物披露，截至2026年6月30日公司股东户数为1.85万户，较3月31日减少523.0户，减幅为2.76%。在化学制药行业个股中，迈威生物股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.67万户。从股价来看，2026年3月31日至2026年6月30日，迈威生物区间跌幅为21.55%，在此期间股东户数减少523.0户，减幅为2.76%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000011095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK1161","BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662878488","title":"海欣股份：公司通过锚定投资方式参与迈威生物-B的投资","url":"https://stock-news.laohu8.com/highlight/detail?id=2662878488","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662878488?lang=zh_cn&edition=full","pubTime":"2026-08-25 15:34","pubTimestamp":1787643259,"startTime":"0","endTime":"0","summary":"证券之星消息，海欣股份(600851)08月25日在投资者关系平台上答复投资者关心的问题。投资者提问：海欣集团投资迈威生物-B金额2060.79万元，是一级市场配售还二级市场买入，投资的目的是什么？海欣股份回复：投资者您好，公司通过锚定投资方式参与迈威生物-B的投资，主要目的是为了充分发挥各方优势，提升公司资金使用效率。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500027004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","02493","BK0188","BK0239","600851","BK1161","BK0086","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661400221","title":"8月24日迈威生物跌6.22%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661400221","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661400221?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:32","pubTimestamp":1787560367,"startTime":"0","endTime":"0","summary":"证券之星消息，8月24日迈威生物跌6.22%，收盘报29.23元，换手率4.16%，成交量9.58万手，成交额2.83亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400021807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150815623","title":"迈威生物-B（02493）将于2026年8月30日审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1150815623","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150815623?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:42","pubTimestamp":1787128925,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司（股票代码：02493，以下简称“迈威生物-B”或“公司”）公告称，公司董事会已排期于2026年8月30日召开会议，审议并通过集团截至2026年6月30日止六个月的中期业绩，并处理其他事项。\n根据公告，目前公司董事会成员包括：执行董事唐春山、董事长兼执行董事刘大涛、执行董事武海、执行董事华俊、执行董事桂勋；独立非执行董事秦正余、周睿、李凡及王芳。\n公告强调，香港交易及结算所有限公司及香港联合交易所有限公司对本公告内容概不负责，并对其准确性或完整性不作任何声明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660844521","title":"8月19日迈威生物跌5.45%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660844521","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660844521?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:40","pubTimestamp":1787128853,"startTime":"0","endTime":"0","summary":"证券之星消息，8月19日迈威生物跌5.45%，收盘报31.38元，换手率3.45%，成交量7.94万手，成交额2.54亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900028318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mabwell.com","stockEarnings":[{"period":"1week","weight":-0.0715},{"period":"1month","weight":-0.0238},{"period":"3month","weight":-0.0765},{"period":"6month","weight":-0.2576},{"period":"ytd","weight":-0.2576}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":-0.0214},{"period":"3month","weight":-0.0118},{"period":"6month","weight":0.0003},{"period":"1year","weight":-0.0112},{"period":"ytd","weight":-0.0117}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"公司是一家全产业链布局的创新型生物制药公司,始终秉承“让创新从梦想变成现实”的愿景,践行“探索生命,惠及健康”的使命,通过源头创新,为患者提供疗效更好、可及性更强的生物创新药,满足全球未被满足的临床需求。公司主营业务为研发、生产以及销售创新型药物和生物类似药。公司主要产品为抗体、ADC药物和重组蛋白、小分子化学药等药物。公司荣誉:上海产业人才队伍建设工作“优秀案例奖”、澳洲会计师公会“认可雇主”、星耀榜“2021中国生物创新药最具成长性年度大奖”、中国医药人才品牌榜总榜及最具竞争力品牌等。","exchange":"SEHK","name":"迈威生物-B","nameEN":"MABWELL-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物-B(02493)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物-B,02493,迈威生物-B股票,迈威生物-B股票老虎,迈威生物-B股票老虎国际,迈威生物-B行情,迈威生物-B股票行情,迈威生物-B股价,迈威生物-B股市,迈威生物-B股票价格,迈威生物-B股票交易,迈威生物-B股票购买,迈威生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物-B(02493)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}